These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 21690412)

  • 21. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies.
    Müller KM; Arndt KM; Strittmatter W; Plückthun A
    FEBS Lett; 1998 Jan; 422(2):259-64. PubMed ID: 9490020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
    Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells.
    Joshi KK; Phung W; Han G; Yin Y; Kim I; Sandoval W; Carter PJ
    MAbs; 2019 Oct; 11(7):1254-1265. PubMed ID: 31286843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.
    Dimasi N; Fleming R; Sachsenmeier KF; Bezabeh B; Hay C; Wu J; Sult E; Rajan S; Zhuang L; Cariuk P; Buchanan A; Bowen MA; Wu H; Gao C
    MAbs; 2017 Apr; 9(3):438-454. PubMed ID: 28055299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
    J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
    Metz S; Panke C; Haas AK; Schanzer J; Lau W; Croasdale R; Hoffmann E; Schneider B; Auer J; Gassner C; Bossenmaier B; Umana P; Sustmann C; Brinkmann U
    Protein Eng Des Sel; 2012 Oct; 25(10):571-80. PubMed ID: 22976197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
    Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
    J Immunol Methods; 2002 Sep; 267(2):213-26. PubMed ID: 12165442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.
    Wranik BJ; Christensen EL; Schaefer G; Jackman JK; Vendel AC; Eaton D
    J Biol Chem; 2012 Dec; 287(52):43331-9. PubMed ID: 23118228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
    Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
    Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies.
    Han L; Zong H; Zhou Y; Pan Z; Chen J; Ding K; Xie Y; Jiang H; Zhang B; Lu H; Gilly J; Zhu J
    Methods; 2019 Feb; 154():32-37. PubMed ID: 30308314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An efficient route to the production of an IgG-like bispecific antibody.
    Zuo Z; Jimenez X; Witte L; Zhu Z
    Protein Eng; 2000 May; 13(5):361-7. PubMed ID: 10835110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical generation of bispecific antibodies.
    Doppalapudi VR; Huang J; Liu D; Jin P; Liu B; Li L; Desharnais J; Hagen C; Levin NJ; Shields MJ; Parish M; Murphy RE; Del Rosario J; Oates BD; Lai JY; Matin MJ; Ainekulu Z; Bhat A; Bradshaw CW; Woodnutt G; Lerner RA; Lappe RW
    Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22611-6. PubMed ID: 21149738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering bispecific antibodies with defined chain pairing.
    Krah S; Sellmann C; Rhiel L; Schröter C; Dickgiesser S; Beck J; Zielonka S; Toleikis L; Hock B; Kolmar H; Becker S
    N Biotechnol; 2017 Oct; 39(Pt B):167-173. PubMed ID: 28137467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
    Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
    MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
    Golay J; Choblet S; Iwaszkiewicz J; Cérutti P; Ozil A; Loisel S; Pugnière M; Ubiali G; Zoete V; Michielin O; Berthou C; Kadouche J; Mach JP; Duonor-Cérutti M
    J Immunol; 2016 Apr; 196(7):3199-211. PubMed ID: 26921308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.
    Jackman J; Chen Y; Huang A; Moffat B; Scheer JM; Leong SR; Lee WP; Zhang J; Sharma N; Lu Y; Iyer S; Shields RL; Chiang N; Bauer MC; Wadley D; Roose-Girma M; Vandlen R; Yansura DG; Wu Y; Wu LC
    J Biol Chem; 2010 Jul; 285(27):20850-9. PubMed ID: 20444694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A modular IgG-scFv bispecific antibody topology.
    Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
    Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.